Since intravenously injected CAR‐HMs must first adhere and transmigrate across the vascular endothelium before entering into tumor tissues, we assessed the trans‐endothelial migration and vascular adhesion capacity of CEA‐activated CAR‐HMs. This evidence concerns the gene CEACAM5 and neoplasm.